Yesim Gökmen-Polar

Apr 6, 2023 | medscape.com | Sunil S. Badve |Yesim Gökmen-Polar

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel The breast cancer world is somewhat fortunate to have biomarkers that are great at selecting patients most likely to respond to targeted therapies. The stratification of breast cancer into estrogen receptor–positive (ER+) and ER-negative disease has stood the test of time.